Table 1 Patient characteristics of standard-dose group and over-dose group
From: High cumulative doxorubicin dose for advanced soft tissue sarcoma
Characteristics | Standard-dose group (n = 146) | Over-dose group (n = 24) |
|---|---|---|
Gender | ||
Male | 70 (47.95%) | 14 (58.33%) |
Female | 76 (52.05%) | 10 (41.67%) |
Age | 43.30 ± 12.10 | 38.58 ± 14.01 |
ECOG PS | ||
0 | 71 (48.63%) | 7 (29.17%) |
1 | 75 (51.37%) | 17 (70.83%) |
Histological types | ||
Undifferentiated sarcoma | 36 (24.66%) | 6 (25.00%) |
Synovial sarcoma | 23 (15.75%) | 4 (16.67%) |
Leiomyosarcoma | 20 (13.70%) | 3 (12.50%) |
Fibrosarcoma | 16 (10.96%) | 3(10.34%) |
Liposarcoma | 15 (10.27%) | 2 (8.33%) |
Angiosarcoma | 14 (9.59%) | 6 (25.00%) |
Epithelioid sarcoma | 7 (4.79%) | |
MPNST | 7 (4.79%) | |
Clear cell sarcoma | 3 (2.05%) | |
Others | 5 (3.42%) | |
Metastatic or locally unresectable | ||
Locally unresectable | 20 (13.70%) | 7 (29.17%) |
Metastatic | 120 (82.20%) | 17 (70.83%) |
Both | 6 (4.11%) | 0 |
Primary site | ||
Extremities | 101 (69.18%) | 14 (58.33%) |
Trunk | 45 (30.82%) | 10 (41.67%) |
Metastatic site | ||
Lung | 124 (84.93%) | 16 (66.67%) |
Other | 22 (15.07%) | 8 (33.33%) |
Mean cycles of doxorubicin chemotherapy | 5 | 11.5 |